Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation
- PMID: 9149145
- DOI: 10.1006/jmbi.1996.0850
Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation
Abstract
We have developed a novel method to stabilize a recombinant antibody Fv fragment. The V(H) and V(L) domains of this Fv fragment, called pFv (permutated Fv), are covalently interconnected to each other at the two "base-loops" that normally connect V(H) beta strand 3 to 3b and V(L) beta strand 3 to 3b. To produce the base-loop stabilized Fv fragment, we connected the N-terminal half of the V(L) domain (V(L) 1-40) of murine antibody anti-Tac to the C-terminal half of V(H) (V(H) 42-115). We also fused the C terminus of V(H) by a (Gly4Ser)3 linker to the N-terminal half of V(H) (V(H) 1-40, thereby generating a permutated V(H) domain). Finally we connected the base loop of V(H) (N-terminal half) to the C-terminal half of V(L) (V(H) 42-115). The anti-Tac pFv fragment was fused to a truncated form of Pseudomonas exotoxin to generate a pFv-immunotoxin. Fvs with the correct structure were produced by refolding of recombinant inclusion body protein using a renaturation protocol that was originally developed for Fab and scFv fragments. Due to the artificially connected and permutated primary sequence, the folding pathway for the pFv structure may possibly be different from the conventional folding of antibody domains. Analysis of antigen binding of anti-Tac pFv, and of the specific cytotoxicity of pFv-immunotoxin towards antigen expressing cancer cells demonstrated that the anti-Tac pFv retained most of its affinity and full specificity when compared to anti-Tac scFv. Also anti-Tac pFv was relatively stable, retaining 25% of its binding activity after a 24 hour incubation in human serum at 37 degrees C. This indicates that connection of base loops can be a useful alternative to linker or disulfide stabilization of Fv fragments.
Similar articles
-
Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.Cancer Res. 1994 May 15;54(10):2714-8. Cancer Res. 1994. PMID: 8168102
-
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin.Nature. 1989 Jun 1;339(6223):394-7. doi: 10.1038/339394a0. Nature. 1989. PMID: 2498664
-
Helix-stabilized Fv (hsFv) antibody fragments: substituting the constant domains of a Fab fragment for a heterodimeric coiled-coil domain.J Mol Biol. 2001 Sep 7;312(1):221-8. doi: 10.1006/jmbi.2001.4915. J Mol Biol. 2001. PMID: 11545598
-
Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.Clin Cancer Res. 1996 Feb;2(2):245-52. Clin Cancer Res. 1996. PMID: 9816166 Review.
-
Recombinant antibody fragments and immunotoxin fusions for cancer therapy.In Vivo. 2000 Jan-Feb;14(1):21-7. In Vivo. 2000. PMID: 10757057 Review.
Cited by
-
Characterization of the inhibition mechanism of a tissuefactor inhibiting single-chain variable fragment: a combined computational approach.J Mol Model. 2020 Mar 26;26(4):87. doi: 10.1007/s00894-020-4350-7. J Mol Model. 2020. PMID: 32219568
-
Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vivo.Jpn J Cancer Res. 1998 May;89(5):583-8. doi: 10.1111/j.1349-7006.1998.tb03301.x. Jpn J Cancer Res. 1998. PMID: 9685864 Free PMC article.
-
Structural and thermodynamic analysis of a conformationally strained circular permutant of barnase.Biochemistry. 2009 Apr 21;48(15):3497-507. doi: 10.1021/bi900039e. Biochemistry. 2009. PMID: 19260676 Free PMC article.
-
Engineering an artificial zymogen by alternate frame protein folding.Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2824-9. doi: 10.1073/pnas.0907668107. Epub 2010 Jan 26. Proc Natl Acad Sci U S A. 2010. PMID: 20133757 Free PMC article.
-
Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct.Cancer Biother Radiopharm. 2008 Aug;23(4):411-23. doi: 10.1089/cbr.2007.0450. Cancer Biother Radiopharm. 2008. PMID: 18771345 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources